A real-world study flagged this month found that tirzepatide (sold as Zepbound for obesity and Mounjaro for diabetes) causes more muscle loss than semaglutide (Ozempic, Wegovy) at the same amount of weight reduction.

This is not a new mechanism, but it is newly visible. Every drug in the current weight-loss class works mostly by suppressing appetite. Patients eat less, and they lose both fat and muscle in a roughly three-to-one ratio. That has been stable across the class. What the new data suggests is that tirzepatide may push that ratio in a less favorable direction, meaning more of the weight lost is muscle. The separate SURMOUNT-5 head-to-head trial ↗ already showed tirzepatide produces more total weight loss. More total plus a worse ratio means a bigger muscle penalty in absolute terms.

Why muscle matters. It drives metabolism, physical function, and long-term recovery from illness. Losing fat is the point of the drug; losing muscle is the hidden cost. The cost becomes sharper with age, with longer treatment duration, and in patients who were already thin or deconditioned.

What fixes it, in the drug-design sense. Adding a third hormone receptor to the drug — specifically, the glucagon receptor — drives fat burning through a different pathway that does not demand the same kind of muscle loss. Glucagon on its own raises blood sugar, which is a problem for diabetic patients, so the dose has to be carefully balanced with the GLP-1 component. The ratio is the design problem.

This is where current development is pointing. One company, MetaVia, recently locked a 40-patent portfolio through 2041 for DA-1726, a dual GLP-1 / glucagon drug ↗ at a 3-to-1 ratio. Early data shows about 9% weight loss with preserved muscle in animal comparisons against both semaglutide and tirzepatide. Lilly has a triple-receptor drug called retatrutide in late-stage trials that adds glucagon and a third target on top of tirzepatide's two.

Another exit, separate from the GLP-1 class entirely, is an older class of drugs called myostatin inhibitors (bimagrumab is the most-studied). These can be taken alongside a weight-loss drug and prevent the muscle loss directly, without touching the appetite-suppression pathway.

A note from our side. Our GLP-1 receptor ↗, GIP receptor ↗, and glucagon receptor ↗ pages catalog candidate molecules across the space. Retatrutide itself is on the platform as pep-00018 ↗. The next generation of obesity drugs will be measured not just on total weight loss, but on how much muscle survives it. Card-level design can address that directly, before clinical trials do.

The weight-loss question is not "how much can we lose." The question is "how much of it is fat, and how much of it comes back differently."